SCHEDULE: Decagon Asset Management Reports Stake in Oaktree Acquisition III

Decagon Asset Management LLP and Benjamin John Durham have reported beneficial ownership of 5.52% of Oaktree Acquisition Corp. III Life Sciences' Class A ordinary shares.

Summary

• Decagon Asset Management LLP and Benjamin John Durham have filed a Schedule 13G, indicating their beneficial ownership of Oaktree Acquisition Corp. III Life Sciences' Class A ordinary shares.
• The total number of shares beneficially owned is 1,091,327, representing 5.52% of the class.
• Both reporting persons have sole voting power and sole dispositive power over these shares.
• The filing date for this event is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Decagon Asset Management LLP and Benjamin John Durham have taken a significant stake (5.52%) in Oaktree Acquisition Corp. III Life Sciences, potentially indicating confidence in the company's future prospects.
• The reporting persons possess sole voting and dispositive power, suggesting clear control over their investment.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Oaktree Acquisition Corp. III Life Sciences, limiting insight into the company's operational health.
• The nature of the acquisition and the specific investment strategy behind it are not detailed.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not inherently contain forward-looking statements or risk factors specific to Oaktree Acquisition Corp. III Life Sciences' operations.
• The investment is subject to market fluctuations and the general risks associated with special purpose acquisition companies (SPACs).

Future Outlook

This filing is a report of beneficial ownership and does not contain forward-looking statements or guidance regarding the future performance of Oaktree Acquisition Corp. III Life Sciences.

Management Comments

• Olivia Cooper, COOD of Decagon Asset Management LLP, certified the accuracy of the filing.
• Ben Durham, CIO of Decagon Asset Management LLP, certified the accuracy of the filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, particularly SPACs. This filing indicates a notable investment by Decagon Asset Management in Oaktree Acquisition Corp. III Life Sciences.

Stakeholder Impact

• Shareholders may view the increased stake by Decagon Asset Management as a positive signal, potentially increasing investor confidence.
• The market may react to the disclosure of a significant ownership position, potentially influencing trading activity.

Next Steps

• Oaktree Acquisition Corp. III Life Sciences will continue its operations and pursuit of a business combination.
• Decagon Asset Management LLP and Benjamin John Durham will continue to hold and potentially manage their investment in the company.

Key Dates

Keywords

Oaktree Acquisition Corp. III Life Sciences, Decagon Asset Management LLP, Benjamin John Durham, Schedule 13G, Beneficial Ownership, Class A ordinary shares, Investment Stake